mglu7 receptor

VU6005649 是一种中枢神经系统渗透性的mGlu7 8受体激动剂，对于mGlu7受体和mGlu8受体的EC50分别为 0.65 μM 和 2.6 μM。

VU6012962 是一种可渗透 CNS ，可口服的代谢型谷氨酸受体 7 阴性变构调节剂，IC50为 347 nM。

VU0361737 (ML-128) 是一种高效选择性的，中枢神经系统渗透性的代谢型谷氨酸受体 4(mGluR4)正变构调节剂，对人类和大鼠 mGluR4作用的EC50值分别为 240 和 110 nM。它具有神经保护作用，有用于帕金森氏病的研究潜力。

allosteric mGlu7-selective receptor antagonist

L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively[1][2]. L-AP4 (5-30 μg, intrathecal inhection 4-5 days) significantly increases the paw withdrawal threshold in response to application of von Frey filaments in eight nerve-ligated rats in a dose-dependent manner. Intrathecal administration of different doses of L-AP4 is not associated with any evident motor dysfunction[2].Intrathecal injection of 30 μg of L-AP4 does not significantly alter the paw withdrawal latency in these normal rats[2].Topical application of 5 to 50 μM L-AP4 to the spinal cord significantly inhibited the evoked response of neurons to touch, pressure, pinch, and von Frey filaments in a concentration-dependent fashion[2]. Animal Model: Rats.[2] [1]. Selvam C, et al. Increased Potency and Selectivity for Group III Metabotropic Glutamate Receptor Agonists Binding at Dual sites. J Med Chem. 2018 Mar 8;61(5):1969-1989. [2]. Chen SR, et al. Distinct roles of group III metabotropic glutamate receptors in control of nociception and dorsal horn neurons in normal and nerve-injured Rats. J Pharmacol Exp Ther. 2005 Jan;312(1):120-6.